Phase 1 Evaluation of BL-B01D1 Safety, Tolerability, and Efficacy in Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

The primary objective of this Phase 1 study is to evaluate the **safety**, **tolerability**, and **efficacy** of BL-B01D1 in subjects with metastatic or unresectable **non-small cell lung cancer** and other solid tumors. This is clinically relevant as it aims to determine the potential therapeutic benefits and risks associated with BL-B01D1, which could inform future treatment options for patients with these challenging oncological conditions.

The clinical trial involves a total of **196 participants** diagnosed with **oncology** conditions. The study population includes both male and female subjects, with an age range spanning from **18 to 64 years**. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria. The selection process aimed to encompass a diverse group within the specified age range, ensuring a comprehensive evaluation of the study's outcomes.

The clinical trial is designed to evaluate the safety, tolerability, and efficacy of a novel therapeutic agent in subjects with **metastatic or unresectable non-small cell lung cancer** and other solid tumors. This is a Phase 1 study, which will be conducted as a randomized, double-blind, controlled trial. The estimated recruitment start date is May 31, 2024, with an anticipated end date of August 30, 2025. The trial will involve multiple study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Participants who meet the inclusion criteria will be randomized to receive either the investigational product or a control. Follow-up visits will be scheduled at regular intervals to monitor safety, tolerability, and any adverse events, as well as to assess the efficacy of the treatment. The end-of-study visit will occur after the final treatment cycle, where comprehensive evaluations will be conducted to gather data on the primary and secondary endpoints. The expected length of participant involvement will vary depending on individual response and tolerance to the treatment, but it is anticipated to last until the end of the study period. Conditions that may lead to early termination from the study include significant adverse reactions, disease progression, or withdrawal of consent by the participant. The trial aims to provide valuable insights into the potential benefits and risks associated with the investigational therapy in the target population.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it has orphan drug status. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments, including their names, dosages, or administration routes. The trial documentation does not specify any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on May 31, 2024, with an estimated completion date of August 30, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, consistent with the standards of Phase 3 clinical trials. The assessment will likely involve validated scales, laboratory tests, or patient-reported outcomes, measured at predetermined timepoints throughout the study duration. The trial's design and execution will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy data collected.